Insmed Inc Stock Short Ratio
| INSM Stock | USD 75.16 0.72 0.95% |
Insmed Inc fundamentals help investors to digest information that contributes to Insmed's financial success or failures. It also enables traders to predict the movement of Insmed Stock. The fundamental analysis module provides a way to measure Insmed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Insmed stock.
Insmed | Short Ratio |
Insmed Inc Company Short Ratio Analysis
Insmed's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Insmed Short Ratio | 8.80 X |
Most of Insmed's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Insmed Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Insmed Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Insmed is extremely important. It helps to project a fair market value of Insmed Stock properly, considering its historical fundamentals such as Short Ratio. Since Insmed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Insmed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Insmed's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Insmed Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Insmed Inc has a Short Ratio of 8.8 times. This is 125.64% higher than that of the Biotechnology sector and 18.76% higher than that of the Health Care industry. The short ratio for all United States stocks is 120.0% lower than that of the firm.
Insmed Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insmed's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insmed could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics of similar companies.Insmed is currently under evaluation in short ratio category among its peers.
Insmed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Insmed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Insmed's managers, analysts, and investors.Environmental | Governance | Social |
Insmed Institutional Holders
Institutional Holdings refers to the ownership stake in Insmed that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Insmed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Insmed's value.| Shares | Artisan Partners Limited Partnership | 2024-09-30 | 2.9 M | Macquarie Group Ltd | 2024-06-30 | 2.7 M | Franklin Resources Inc | 2024-09-30 | 2.7 M | Ameriprise Financial Inc | 2024-06-30 | 2.5 M | Suvretta Capital Management, Llc | 2024-06-30 | 2.5 M | Alliancebernstein L.p. | 2024-06-30 | 2.5 M | William Blair Investment Management, Llc | 2024-09-30 | 2.4 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 2.3 M | Hhg Plc | 2024-06-30 | 2.1 M | Vanguard Group Inc | 2024-09-30 | 17.1 M | Blackrock Inc | 2024-06-30 | 14.3 M |
Insmed Fundamentals
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.52) % | ||||
| Operating Margin | (2.13) % | ||||
| Current Valuation | 13.11 B | ||||
| Shares Outstanding | 178.9 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 99.09 % | ||||
| Number Of Shares Shorted | 12.1 M | ||||
| Price To Earning | (8.70) X | ||||
| Price To Book | 28.08 X | ||||
| Price To Sales | 39.58 X | ||||
| Revenue | 305.21 M | ||||
| Gross Profit | 190.23 M | ||||
| EBITDA | (654.74 M) | ||||
| Net Income | (749.57 M) | ||||
| Cash And Equivalents | 554.87 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 1.2 B | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 2.70 X | ||||
| Cash Flow From Operations | (536.25 M) | ||||
| Short Ratio | 8.80 X | ||||
| Earnings Per Share | (5.55) X | ||||
| Target Price | 89.4 | ||||
| Number Of Employees | 912 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 13.58 B | ||||
| Total Asset | 1.33 B | ||||
| Retained Earnings | (3.45 B) | ||||
| Working Capital | 703.43 M | ||||
| Current Asset | 28.15 M | ||||
| Current Liabilities | 3.89 M | ||||
| Net Asset | 1.33 B |
About Insmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insmed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Insmed Piotroski F Score and Insmed Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.